Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy

Diagnostic Microbiology and Infectious Disease

Volumn 64, Issue 3, 2009, Pages 354-356

  Shahid, Zainab ^a   Sobel, Jack D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Candida albicans; Fluconazole; Susceptibility; Vagina

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; TRIAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CANDIDA ALBICANS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA CANDIDIASIS;

ADULT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS, VULVOVAGINAL; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RECURRENCE; YOUNG ADULT;

EID: 66149160380     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2009.03.021     Document Type: Article

References (18)

1. Arzeni D., et al. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy. Eur. J. Epidemiol. 13 (1997) 447-450
2. Centers for Disease Control. Sexually transmitted diseases treatment guidelines. MMWR 55 (2006) RR--11
3. Dorrell L., and Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex. Transm. Infect. 78 (2002) 308-309
4. El-Din S.S., et al. An investigation into the pathogenesis of vulvovaginal candidosis. Sex. Transm. Infect. 77 (2001) 179-183
5. Fichtenbaum C.J., et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin. Infect. Dis. 30 (2000) 749-756
6. Houang E.T., et al. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single dose and rate of eradication of infection in vaginal candidiasis. Antimicrob. Agents Chemother. 34 (1990) 909-910
7. Lynch M.E., and Sobel J.D. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J. Med. Vet. Mycol. 32 (1994) 267-274
8. Mardh P.A., et al. Facts and myths on recurrent vulvovaginal candidosis-a review on epidemiology, clinical manifestation, diagnosis, pathogenesis and therapy. Int. J. STD AIDS 13 (2002) 522-539
9. Maslow J.N., et al. Application of pulsed-field gel electrophoresis to molecular epidemiology. In: Persing D.H., Smith T.F., Tenover F.C., and White T.J. (Eds). Diagnostic molecular microbiology: principles and applications, American Society for Microbiology (1993) 563-572 Washington, DC
10. National Committee for Clinical Laboratory Standards. Reference methods for broth dilution antifungal susceptibility testing for yeasts. Approved standards M27-A2. Second Edition (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
11. Rex J.H., et al. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39 (1995) 1-8
12. Ribeiro M.A., et al. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologica 151 (2000) 5-10
13. Richter S.S., et al. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol. 43 (2005) 2155-2162
14. Sobel J.D., and Vazquez J.A. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin. Infect. Dis. 22 (1996) 726-727
15. Sobel J.D., et al. HIV Epidemiology Research (HERS) Group. The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus(HIV)-seropositive and at-risk HIV-seronegative women. J. Infect. Dis. 183 (2001) 286-293
16. Sobel J.D., et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med 351 (2004) 876-883
17. Sobel J.D., et al. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis clinical implications. Antimicrob. Agents Chemother. 47 (2003) 34-38
18. Vazquez J.A., et al. Evolution of antifungal susceptibility among candid species isolates recovered from human immunodeficiency virus infected women receiving fluconazole prophylaxis. Clin. Infect. Dis. 31 (2001) 1069-1075